Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 16/20 | 0.53 |
| ▸ | PPARG | P37231 | 11/20 | 0.53 |
| ▸ | RARG | P13631 | 7/20 | 0.53 |
| ▸ | RARA | P10276 | 5/20 | 0.48 |
| ▸ | RXRB | P28702 | 5/20 | 0.48 |
| ▸ | RXRG | P48443 | 5/20 | 0.48 |
| ▸ | RARB | P10826 | 4/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585853 | 1.00 | RXRA (0.53) | RXRAPPARGRARGRARARXRB | |
| SCHEMBL4585861 | 1.00 | RXRA (0.53) | RXRAPPARGRARGRARARXRB | |
| SCHEMBL6917046 | 1.00 | RXRA (0.53) | RXRAPPARGRARGRARARXRB | |
| SCHEMBL6917051 | 1.00 | RXRA (0.53) | RXRAPPARGRARGRARARXRB | |
| SCHEMBL6914089 | 0.82 | RXRA (0.62) | RXRAPPARGRARGRARARXRB | |
| SCHEMBL4586145 | 0.82 | RXRA (0.62) | RXRAPPARGRARGRARARXRB | |
| SCHEMBL4586143 | 0.82 | RXRA (0.62) | RXRAPPARGRARGRARARXRB | |
| SCHEMBL6914091 | 0.82 | RXRA (0.62) | RXRAPPARGRARGRARARXRB | |
| SCHEMBL4586142 | 0.82 | RXRA (0.62) | RXRAPPARGRARGRARARXRB | |
| SCHEMBL6908862 | 0.80 | RXRA (0.56) | RXRAPPARGRARGRARARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453496-A4 | COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY | ALLERGAN INC (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20050004165-A1 | Composition and method for modulating BAR/FXR receptor activity | FORMAN BARRY M (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1453496-A2 | COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY | Allergan, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030144360-A1 | Composition and method for modulating BAR/FXR receptor activity | ALLERGAN SALES, INC. | 2003-07-31 | — | — | US | disclosed |
| WO-2003043581-A2 | COMPOSITION AND METHOD FOR MODULATING BAR/FXR RECEPTOR ACTIVITY | ALLERGAN, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004165-A1 | Composition and method for modulating BAR/FXR receptor activity | NR1H4, FXR1, GPBAR1 | RXRA 35/4885PPARG 96/4885RARG 150/4885 |
| US-20030144360-A1 | Composition and method for modulating BAR/FXR receptor activity | NR1H4, FXR1, GPBAR1 | RXRA 35/4885PPARG 96/4885RARG 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.